Incidence of Carbapanemase Resistance Gene (KPC) among Klebsiella pneumoniae isolates and its Clinical Implications  by Yegneswaran, B. et al.
trac
a
o
p
p
t
r
a
r
b
t
t
p
a
o
b
K
l
i
C
m
c
g
d
2
I
C
M
J
M
1
S
2
3
4
o
a
m
i
r
i
g
t
r
t
e
c
S14th International Congress on Infectious Diseases (ICID) Abs
Methods: Sixty isolates were identiﬁed as Acinetobacter
species. The isolates were tested for antibiotic resistance by
disc diffusion method for 12 antimicrobials. The presence of
aphA6, aacC1 aadA1, and aadB genes were detected using
PCR.
Results: From the isolated Acinetobacter spp. the highest
resistance rate showed against amikacin, tobramycin, and
ceftazidim, respectively; while isolated bacteria were more
sensitive to ampicillic/subactam. More than 66% of the iso-
lates were resistant to at least three classes of antibiotics,
and 27.5% of MDR strains were resistant to all seven tested
classes of antimicrobials. The higher MDR rate presented
in bacteria isolated from the ICU and blood samples. More
than 60% of the MDR bacteria were resistance to amikacin,
ceftazidim, ciproﬂoxacin, piperacillin/tazobactam, doxy-
cycline, tobramycin and levoﬂoxacin. Also, more than
60% of the isolates contained phosphotransferase aphA6,
and acetyltransferase genes aacC1, but adenylyltransferase
genes aadA1 (41.7%), and aadB (3.3%) were less prominent.
In this study 21.7% of the strains contain three aminoglyco-
side resistance genes (aphA6, aacC1 and aadA1).
Conclusion: The rising trend of resistance to amino-
glycosides poses an alarming threat to treatment of such
infections. The ﬁndings showed that clinical isolates of
Acinetobacter spp. in our hospital carrying various kinds of
aminoglycoside resistance genes.
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Background: Carbapenem antibiotics (Imipenem,
Ertapenem, and Meropenem) idicated for infections caused
by extended-spectrum {beta}-lactamase (ESBL) carrying
pathogens. Carbapenem resistance has been unusual in
isolates of Klebsiella pneumoniae. The aim of this study
is to identify the prevalence of KPC positive Klebsiella
pneumoniae, and it’s clinical signiﬁcance.
Methods: All isolates of Klebsiella pneumoniae species
from October 1, 2007 to September 30, 2009 were tested
for the presence of KPC gene using the modiﬁed Hodge test.
Medical records of patients with KPC were studied.
Results: Over the period of two-years 40,309 samples
were submitted for culture and sensitivity, out of which
7,836 were positive. Of the positives, there were 106 iso-
lates of K pneumoniae and 11 were ESBL positive. Of
the ESBL producing isolates, 8 carried the Carbapenem-
hydrolyzing -lactamase. Of the eight, three isolates were
reported as being susceptible to Imipenem. Although all
the eight isolates were resistant using the Hodge test.
Piperacillin/Tazobactam (PT) and Vancomycin were the
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ntibiotic used 7 of the 8 patients prior to isolation
f Klebsiella pneumoniae resistant to Carbapenems. One
atient was excluded in outcome as one patient’s sam-
le was clinically thought to be a contaminant was not
reated. 3 patients in whom resistance to carbapenem was
eported had their antibiotic was changed to Tigecycline
nd Polymyxin B resulting in clinical improvement. Of the
emaining 4 patients who were reported as sensitive to car-
apenem three patients had to undergo a repeat surgery due
o clinical deterioration and one patient clinically died.
Conclusion: The incidence of KPC gene at our hospi-
al was 7.5%. KPC positive isolatesare rapidly emerging
athogens. It is very important to keep this organism in mind
s if not treated there is a 100% probability of having a poor
utcome. There is a complete cross resistance to all Car-
apenems containing KPC, therefore if KPC is present, the
pneumoniae will be resistant to all Carbapenem regard-
ess of the routine susceptibility testing as shown in three
solates that are KPC positive but susceptible to Imipenem.
urrent automated systems used for susceptibility testing
ay not accurately identify all these isolates. We must also
ontrol the use of antibiotics specially PT to prevent emer-
ence of KPC positive organisms.
oi:10.1016/j.ijid.2010.02.1564
3.009
n vitro activity of Tigecycline against molecularly deﬁned
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Background: Acinetobacter baumannii are important
pportunistic pathogens with increasing rates of multi-
ntibiotic resistance due to both intrinsic and acquired
echanisms. Carbapenems are often used to treat these
nfections, however carbapenem resistance is increasingly
eported, leaving few therapeutic options. This resistance
s most often associated with acquired or intrinsic OXA-
roup carbapenemase production. While A. baumannii carry
he intrinsic OXA-51-like carbapenemase gene, carbapenem
esistance has only been associated with these genes when
he insertion sequence ISAba1 is upstream. In this study, we
valuated the in vitro activity of tigecycline against geneti-
ally deﬁned A. baumannii from the Tigecycline Evaluation
urveillance Trial.Methods: A total 352 imipenem resistant Acinetobacter
aumanii from 35 countries (2004 to 2006) were evaluated.
ICs were determined by broth microdilution and inter-
reted according to CLSI guidelines. Carbapenemase genes
ere detected by multiplex PCR.
